Abstract LB439: HP568, a highly potent and orally bioavailable ER PROTAC for breast cancer treatment, currently undergoing phase 1/2 clinical studies
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Jing Li, Zhilin Tu, Luchan Deng, Zhipeng Quan, Wu Du, Xinghai Li
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4409821013